Modeled fetal risk of genetic diseases identified by expanded carrier screening

JAMA - Journal of the American Medical Association

Volumn 316, Issue 7, 2016, Pages 734-742

  Haque, Imran S ^a   Lazarin, Gabriel A ^a   Kang, H Peter ^a   Evans, Eric A ^a   Goldberg, James D ^a   Wapner, Ronald J ^b  

^a Departments of Medical Affairs and Research Counsyl ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN; AFRICAN AMERICAN; ARTICLE; ASHKENAZI JEW; CONTROLLED STUDY; CYSTIC FIBROSIS; EAST ASIAN; ETHNIC DIFFERENCE; FEMALE; FETUS RISK; FRAGILE X SYNDROME; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; HEMOGLOBINOPATHY; HETEROZYGOSITY; HETEROZYGOTE; HISPANIC; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; RECESSIVE INHERITANCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPINAL MUSCULAR ATROPHY; UNITED STATES; AMERICAN INDIAN; ASIAN CONTINENTAL ANCESTRY GROUP; BLACK PERSON; CAUCASIAN; ETHNOLOGY; FETAL DISEASES; GENETIC DISEASES, INBORN; GENETICS; GENOTYPING TECHNIQUE; HETEROZYGOTE DETECTION; HOMOZYGOTE; JEW; NONPARAMETRIC TEST; PROCEDURES; STATISTICS AND NUMERICAL DATA;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FETAL DISEASES; GENETIC DISEASES, INBORN; GENETIC TESTING; GENOTYPING TECHNIQUES; HETEROZYGOTE; HETEROZYGOTE DETECTION; HISPANIC AMERICANS; HOMOZYGOTE; HUMANS; INDIANS, NORTH AMERICAN; JEWS; MALE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; UNITED STATES;

EID: 84987668863     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.11139     Document Type: Article

References (26)

1. ACOG Committee on Obstetrics. ACOG Practice Bulletin No. 78. Obstet Gynecol. 2007;109(1):229-237.
2. Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine-points to consider. Obstet Gynecol. 2015; 125(3):653-662.
3. Lazarin GA, Haque IS, Nazareth S, et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants. Genet Med. 2013; 15(3):178-186.
4. GrodyWW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med. 2013;15(6):482-483.
5. Lazarin GA, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS. Systematic classification of disease severity for evaluation of expanded carrier screening panels. PLoS One. 2014;9(12):e114391.
6. American College of Medical Genetics. Newborn screening. Genet Med. 2006;8(suppl 1):1S-252S.
7. Chan M, ChanMW, Loh TW, et al. Evaluation of nanofluidics technology for high-throughput SNP genotyping in a clinical setting. J Mol Diagn. 2011;13 (3):305-312.
8. Kang HP, Maguire JR, Chu CS, et al. Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing. PeerJ. 2016;4:e2162.
9. Chen L, Hadd A, Sah S, et al. An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. J Mol Diagn. 2010; 12(5):589-600.
10. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants. Genet Med. 2015;17(5):405-424.
11. Henneman L, Borry P, Chokoshvili D, et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet. 2016;24(6):e1-e12.
12. Seymour CA, Thomason MJ, Chalmers RA, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess. 1997;1(11):i-iv, 1-95.
13. Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy. Eur J Hum Genet. 2012;20(1):27-32.
14. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 469. Obstet Gynecol. 2010; 116(4):1008-1010.
15. GrodyWW. Expanded carrier screening and the law of unintended consequences: from cystic fibrosis to fragile X. Genet Med. 2011;13(12):996-997.
16. McConkie-Rosell A, Finucane B, Cronister A, et al. Genetic counseling for fragile X syndrome. J Genet Couns. 2005;14(4):249-270.
17. Sherman S, Pletcher BA, Driscoll DA. Fragile x syndrome. Genet Med. 2005;7(8):584-587.
18. Bailey DB Jr, Raspa M, Bishop E, Holiday D. No change in the age of diagnosis for fragile X syndrome. Pediatrics. 2009;124(2):527-533.
19. Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics. 2010;125(1):e17-e23.
20. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123(1):378-390.
21. Schaefer TL, Davenport MH, Erickson CA. Emerging pharmacologic treatment options for fragile X syndrome. Appl Clin Genet. 2015;8:75-93.
22. Tassone F. Newborn screening for fragile X syndrome. JAMA Neurol. 2014;71(3):355-359.
23. Van Driest SL,Wells QS, Stallings S, et al. Association of arrhythmia-related genetic variants with phenotypes documented in electronic medical records. JAMA. 2016;315(1):47-57.
24. FeeroWG. Establishing the clinical validity of arrhythmia-related genetic variations using the electronic medical record: a valid take on precision medicine JAMA. 2016;315(1):33-35.
25. Narasimhan VM, Hunt KA, Mason D, et al. Health and population effects of rare gene knockouts in adult humans with related parents. Science. 2016;352(6284):474-477.
26. Azimi M, Schmaus K, Greger V, et al. Carrier screening by next-generation sequencing. Molec Genet Genomic Med. 2016;4(3):292-302.